



Pathway developed by Dorset County Hospital  
Reviewed January 2021

References: National Institute for Health and Clinical Excellence (2014) The management of atrial fibrillation.  
European Society of Cardiology (2016) Guidelines for the management of atrial fibrillation.

**Prepare for DC Cardioversion:**  
If on warfarin weekly INRs (Target 2.5-3.0); must have INR >2.0 for four full weeks prior to cardioversion. If on direct oral anti-coagulant (DOAC) ensure strict patient compliance.

**DC Cardioversion – DAY SURGERY UNIT**  
Procedure and then review of medications & onward management plan (Arrhythmia Nurse Specialist/ Cardiology Specialty Registrar).

**4-6 Weeks post procedure: Follow-Up with Arrhythmia Nurse or Dr Boullin** (where a long-term ablation approach has been agreed or likely)  
Is the patient in sinus rhythm and are their symptoms improved/satisfactory?

Yes

No

Review case and patient's wishes; would an ablation approach be suitable?

Yes

No

**Depending on clinical indications and patient preference either:**

1. Re-attempt DC cardioversion with additional Anti-arrhythmic medication
2. Referral for to Dr Boullin for catheter ablation
3. Switch to a rate control strategy & likely discharge
4. Refer to Cardiologist if patient has other cardiac complications

**6 Months post procedure: Follow-Up with Arrhythmia Nurse**  
Is the patient in sinus rhythm and are their symptoms improved/satisfactory?

Yes

No

Discharge to primary care and advised to seek medical attention if symptoms recur

**Depending on clinical indications and patient preference either:**

1. Re-attempt DC cardioversion with additional Anti-arrhythmic cover
2. Referral for to Dr Boullin for catheter ablation
3. Switch to a rate control strategy & likely discharge
4. Refer to Cardiologist if patient has cardiac complications

**Anti-coagulation post DC Cardioversion:**

Maintaining a therapeutic INR or good concordance with other anticoagulation during the four weeks post DC Cardioversion is essential for **ALL** patients regardless of their **CHA2DS2–VASc score**. Advice with regards to long-term anti-coagulation is based on patients' **CHA2DS2–VASc score** rather than the presence of sinus rhythm/absence of atrial fibrillation/flutter on ECG/Holter.

Pathway developed by Dorset County Hospital  
Reviewed January 2021

References: National Institute for Health and Clinical Excellence (2014) The management of atrial fibrillation. European Society of Cardiology (2016) Guidelines for the management of atrial fibrillation.